Man’s best friend may soon owe a collective debt of gratitude to listed Perth Biotech PharmAust, if their dog cancer drug trial is successful.
PharmAust are about to commence a clinical trial of their dog cancer drug “PPL-1” by administering increasing doses to dogs that have cancer.
To-date, 4 dogs with untreatable tumours have been administered with the drug on a compassionate basis with no discernible side effects.
PharmAust have now developed a tasteless, soft gel formula drug which makes the product more palatable for dogs as the company seeks to enter the growing $550 million dollar pet cancer market in the US where there are estimated to be over 75 million pet dogs.
